{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:42:41Z","timestamp":1784040161793,"version":"3.55.0"},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The activated clotting time (ACT) is a useful marker of unfractionated heparin (UFH) activity during cardiopulmonary bypass (CPB) or cardiac catheterization. Emicizumab, recently approved for bleeding prevention in haemophilia A patients, acts like FVIII but does not need prior activation; it therefore shortens coagulation times in assays using intrinsic pathway activators and so is expected to shorten the ACT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluated emicizumab's impact on heparin\u2010induced ACT (Hemochron\u00ae) prolongation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We measured the high\u2010range (HR) ACT in citrated blood samples from healthy donors (HDs) (<jats:italic>n<\/jats:italic>\u00a0=\u00a09), CPB patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a03) and emicizumab\u2010treated patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a05) after spiking with UFH and\/or emicizumab. The low range (LR) ACT was also measured in spiked\u2010samples from HDs and emicizumab\u2010treated patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In HDs, the median [interquartile range] baseline HR\u2010ACTs were similar with and without emicizumab (129 [123\u2013138] and 136 [115\u2013141]\u00a0s for 50\u00a0\u03bcg\/ml, respectively); whatever the concentration of emicizumab (10 to 50\u00a0\u03bcg\/ml), increasing the UFH concentration (1\u20135 UI\/ml) prolonged the HR\u2010ACT. In blood from patients undergoing CPB, the HR\u2010ACT prolongation observed during this procedure was not masked by emicizumab at any concentration. Likewise, the addition of increasing concentrations of UFH to blood from emicizumab\u2010treated patients induced a concentration\u2010dependent prolongation of HR\u2010ACT. Baseline LR\u2010ACT were prolonged in emicizumab\u2010treated patients but as for HR\u2010ACT, emicizumab does not prevent heparin\u2010induced prolongation of LR\u2010ACT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Emicizumab does not interfere with UFH\u2010induced ACT prolongation. The hemochron\u00ae ACT can be used to monitor UFH in patients receiving emicizumab during CPB or cardiac catheterization.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14497","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T13:15:42Z","timestamp":1642770942000},"page":"362-366","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Emicizumab does not interfere with the activated clotting time"],"prefix":"10.1111","volume":"28","author":[{"given":"Ladislas","family":"Capdevila","sequence":"first","affiliation":[{"name":"Haematology Laboratory AP\u2010HP H\u00f4pital Universitaire Necker\u2010Enfants Malades  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Fr\u00e8re","sequence":"additional","affiliation":[{"name":"INSERM UMRS_1166 Institute of Cardiometabolism and Nutrition Sorbonne Universit\u00e9  Paris France"},{"name":"Haematology Laboratory AP\u2010HP H\u00f4pital Universitaire Piti\u00e9\u2010Salp\u00eatri\u00e8re  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilien","family":"Desvages","sequence":"additional","affiliation":[{"name":"Haematology Laboratory AP\u2010HP H\u00f4pital Universitaire Necker\u2010Enfants Malades  Paris France"},{"name":"HITh, UMR_S 1176 INSERM Universit\u00e9 Paris\u2010Saclay  Le Kremlin\u2010Bicetre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Harroche","sequence":"additional","affiliation":[{"name":"Centre de Traitement de l'Hemophilie AP\u2010HP H\u00f4pital Universitaire Necker\u2010Enfants Malades  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Bally","sequence":"additional","affiliation":[{"name":"Centre de Traitement de l'Hemophilie AP\u2010HP H\u00f4pital Universitaire Necker\u2010Enfants Malades  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abbes","sequence":"additional","affiliation":[{"name":"GRC 29; Department of Anaesthesiology and Critical Care Medicine AP\u2010HP Sorbonne Universit\u00e9 H\u00f4pital Universitaire Piti\u00e9\u2010Salp\u00eatri\u00e8re  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4843-7805","authenticated-orcid":false,"given":"Roseline","family":"d'Oiron","sequence":"additional","affiliation":[{"name":"HITh, UMR_S 1176 INSERM Universit\u00e9 Paris\u2010Saclay  Le Kremlin\u2010Bicetre France"},{"name":"Service d'h\u00e9matologie AP\u2010HP H\u00f4pital de Bic\u00eatre  Le Kremlin\u2010Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-2163","authenticated-orcid":false,"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[{"name":"Centre de Traitement de l'Hemophilie AP\u2010HP H\u00f4pital Universitaire Necker\u2010Enfants Malades  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Borgel","sequence":"additional","affiliation":[{"name":"Haematology Laboratory AP\u2010HP H\u00f4pital Universitaire Necker\u2010Enfants Malades  Paris France"},{"name":"HITh, UMR_S 1176 INSERM Universit\u00e9 Paris\u2010Saclay  Le Kremlin\u2010Bicetre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6600-0263","authenticated-orcid":false,"given":"Dominique","family":"Lasne","sequence":"additional","affiliation":[{"name":"Haematology Laboratory AP\u2010HP H\u00f4pital Universitaire Necker\u2010Enfants Malades  Paris France"},{"name":"HITh, UMR_S 1176 INSERM Universit\u00e9 Paris\u2010Saclay  Le Kremlin\u2010Bicetre France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14372"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14318"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13817"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13990"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1692427"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1688687"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13490"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(19)41345-7"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e3182354b7e"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15195"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2019.09.012"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2017.05.012"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_9_15_1","article-title":"Activated coagulation time and hepcon protamine titration device to manage unfractionated heparin during cardiopulmonary bypass in a hemophilia A patient on emicizumab","author":"Isaacs J","year":"2020","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(96)70191-5"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14177"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-801662"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14497","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14497","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T15:42:44Z","timestamp":1692978164000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1111\/hae.14497"],"URL":"https:\/\/doi.org\/10.1111\/hae.14497","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"2021-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}